trending Market Intelligence /marketintelligence/en/news-insights/trending/_bkjwzUTFBAepm_8GkAF3g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Zealand Pharma acquiring Encycle Therapeutics to expand peptide drug development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Zealand Pharma acquiring Encycle Therapeutics to expand peptide drug development

Zealand Pharma A/S will acquire Toronto-based private biotechnology company Encycle Therapeutics Inc. in a bid to expand its peptide platform with Encycle's potential peptide drug that is being developed to target inflammatory bowel disease.

As part of the deal, the Danish biotechnology company will acquire all of Encycle's outstanding shares, its intellectual property, and rights to develop and commercialize the peptide drug, named ET3764. However, it will not acquire any infrastructure or personnel costs.

Zealand, which develops peptide-based medicines mainly for gastrointestinal and metabolic diseases, also gains access to Encycle's screening library of about 5,000 peptide macrocycles that could provide additional targets for research.

The total future consideration of the transaction is likely to reach $80 million in one-time contingent value rights, out of which $10 million in earn-outs will be payable after a successful phase 2 trial of ET3764.

Zealand can pay the earn-outs, which are linked to the completion of certain development, regulatory and commercial-related milestones, either in cash or via equity, according to an Oct. 22 news release.